You are here: SURGERY HOME > RESEARCH > CLINICAL FUNDING
Clinical Funding
Funding listed by physician. Please click on a physician's name to view.
Kelly M. McMasters, MD, PhD
http://www.aboutlivertumors.com
http://www.aboutbreasthealth.com
Schering-Oncology Biotech
Sunbelt Melanoma Trial
Southwestern Oncology Group
Phase III Randomized Study of Four Weeks of High Dose IFN-ÿ2b in Stage T3 – T4 or N1 (microscopic) Melanoma
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with “No Evidence of Disease” after Complete Surgical Resection of “Locally Advanced” and/or Stage IVMelanoma
AVAX
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients with Stage III or IV Melanoma
Comparison of M-Vax Plus Low Dose Interleukin-2 versus Placebo Vaccine plus Low-Dose Interleukin-2 Paitents with Stage IV Melanoma
John Wayne Cancer Institute
Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Prospective Study of the Natural History of Subjects Who Were Entered in the MMAIT-03-001 and MMAIT-04-001 Trials and Underwent Post-Operative Therapy with BCG Plus Placebo or BCG plus Canvaxin
VICAL
A Phase III Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7 Compared to DTIC or TMZ in Subjects with Recurrent Metastatic Melanoma
Veridex, LLC
Identification of Gene Markers to Differentiate Benign and Malignant Melanocytic Skin Lesions
Glen A. Franklin, MD
http://www.uoflhealthcare.org/Default.aspx?tabid=504
Novo Nordisk, Inc.
A multi-center, randomized, double-blind, parallel group, placebo controlledtrial to evaluate the efficacy and safety of activated recombinant factor VII (rFVIIa/NovoSeven®/NiaStase®) in the treatment of refractory bleeding inseverely injured trauma patients
Cadence Pharmaceuticals
A Phase III, multi-center, randomized, evaluation committee-blinded study to assess the efficacy of topical administration of omiganan 1.0% gel in preventing local catheter site infections and catheter colonization in patients undergoing central venous catheterization
Eisai Pharmaceuticals
A controlled comparison of eritoran tetrasodium and placebo in patients with severe sepsis
Susan Galandiuk, MD
http://www.priceinstitute.com/grants/trials.html
http://www.uoflhealthcare.org/Default.aspx?tabid=504
Abbott Pharmaceutical, Inc.
A 5-Year, Non-Interventional Registry Study of HUMIRA® (Adalimumab)in Patients with Moderately to Severely Active Crohn’s Disease (CD) (08.0096)
Quintiles
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to SeverelyActive Ulcerative Colitis (07.0085)
Galandiuk Protocol
The Association of Gastrointestinal Disease, DNA Repair, and Host Defense Genes (361.97)
Galandiuk Protocol
Prospective open label study of a smokeless tobacco product in Crohn’s disease patients with moderately to severely active Crohn’s disease who have failed prior attempts at smoking cessation (323.06)
Pacira Pharmaceutical, Inc.
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects
Richard E. Goldstein, MD, PhD
Pfizer
A Pivotal Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with 131I-refractory Metastatic or Unresectable Locally-advanced Papillary, Follicular, or Hurthle-cell Thyroid Cancer Who are also Refractory to, or Intolerant of, or have Clinical Contraindication to, Doxorubicin Treatment
Charles R. Scoggins, MD
http://www.aboutbreasthealth.com
American College of Surgeons Oncology Group
A Phase III Randomized Double-blind Study of Adjuvant STI571 (GleevecTM) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal Stromal Tumor (GIST):
Novartis
Gastrointestinal Stromal Tumors (GIST) Registry
Neoprobe
Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Lymphoseek as a Lymphoid Tissue Targeting Agent in Patients with Known or Suspected Melanoma or Breast Cancer Who are Undergoing Lymph Node Mapping